Longevity Starts with the Heart: What Every Outdoorsman Should Know About Statins, LDL Particles, and ApoB

When we think about what keeps us wild and active into our 60s, 70s, and beyond, most hunters and anglers point to fitness, grit, and a love of the outdoors. But if there’s one silent threat that can bring even the fittest outdoorsman to his knees, it’s cardiovascular disease.

And here’s the kicker: it often starts decades before symptoms show up.

This article is the first in a series that explores cardiovascular longevity for hunters and anglers. We’re kicking off with a conversation that might make some in our community uncomfortable: cholesterol, statins, and what actually matters when it comes to heart risk. Spoiler alert—it's not just your total cholesterol or even your LDL.

The Real Risk: It’s the Particles, Not Just the Number

For years, cholesterol panels have focused on LDL-C, the “bad” cholesterol. But LDL-C is just a weight estimate—how much cholesterol is floating in low-density lipoprotein (LDL) particles. It doesn’t tell us how many of those particles you actually have.

And that matters. Because the more LDL particles you have, the more likely they are to get stuck in the lining of your arteries, triggering inflammation and plaque buildup.

That’s why many longevity-focused physicians now look at LDL particle count (LDL-P) and Apolipoprotein B (ApoB)instead. ApoB is a protein carried on every atherogenic (plaque-forming) particle, including LDL, VLDL, and IDL. If you have one ApoB, you have one potentially dangerous particle.

In other words, ApoB is the sniper scope of cardiovascular risk. It doesn’t just estimate your cholesterol—it shows how many actual bullets are circulating.

Key targets:

• ApoB: Optimal is < 80 mg/dL for primary prevention; < 60 mg/dL if you already have cardiovascular disease or plaque evidence^1,2.

• LDL-P: Optimal < 1,000 nmol/L for low-risk individuals, ideally < 800 for those with known atherosclerosis³.

How Statins Actually Work

Statins reduce cholesterol production in the liver by inhibiting HMG-CoA reductase, the key enzyme in the cholesterol synthesis pathway. This lowers intracellular cholesterol, prompting the liver to upregulate LDL receptors, which pull more LDL particles out of circulation⁴.

But statins do more than lower LDL:

• They reduce arterial inflammation (lowering hs-CRP)

• They stabilize vulnerable plaques

• They improve endothelial function

Over time, this results in a 25–50% reduction in major cardiovascular events, even in those without prior heart disease⁵.

So What’s the Big Deal with Statins?

Despite being one of the most studied drug classes in medicine, statins have earned a controversial reputation—especially in the outdoor and functional health spaces. Many hunters and fitness-focused men worry that statins will:

• Cause muscle pain or weakness

• Deplete CoQ10 (a key molecule in mitochondrial function)

• Impair testosterone

• Increase the risk of diabetes

Let’s take those concerns seriously—but put them in context.

1. Muscle Aches

Up to 10% of patients in clinical practice report muscle-related symptoms on statins. But controlled trials show much lower rates—often indistinguishable from placebo⁶.

So why the disconnect?

Muscle pain may stem from several mechanisms:

• Disruption of mitochondrial function via decreased CoQ10 synthesis (since CoQ10 shares the mevalonate pathway with cholesterol)⁷

• Altered calcium signaling in muscle cells

• Changes in muscle membrane integrity in genetically susceptible individuals

True statin intolerance is rare, and most people can tolerate lower doses, different agents (e.g., switching from simvastatin to rosuvastatin or pravastatin), or alternate dosing schedules⁸.

What About the Other Concerns?

CoQ10 Depletion

Statins reduce cholesterol by blocking the mevalonate pathway—but this same pathway is also responsible for synthesizing coenzyme Q10 (CoQ10), a fat-soluble compound critical for mitochondrial energy production. CoQ10 helps shuttle electrons in the process of ATP creation, especially in energy-hungry tissues like heart and skeletal muscle. It also acts as a powerful antioxidant.

While statins do reduce serum CoQ10 levels, it's unclear whether this translates to muscle symptoms in most people. However, for high-performing individuals—especially those engaging in sustained aerobic or strength activity—it may make sense to supplement with 100–200 mg of ubiquinol (the active form) daily as a preventive or recovery-supportive measure. Think of it as a small insurance policy for your mitochondria when you're pushing hard in the backcountry

Testosterone and Energy

This is one of the most common concerns among midlife hunters, lifters, and high-output men: “Will a statin tank my T?”

The short answer is no—not meaningfully. But let’s unpack it.

Testosterone is synthesized from cholesterol, so it seems logical to assume that lowering cholesterol might lower testosterone. However, your Leydig cells don’t need much cholesterol to make plenty of testosterone, and the body maintains adequate substrate even when LDL is lowered. Multiple studies and meta-analyses have shown no significant drop in total or free testosterone levels in men taking statins¹⁰.

In fact, some trials even show a small increase in testosterone due to reduced inflammation and improved vascular flow—particularly in men with baseline metabolic dysfunction. Chronic inflammation, oxidative stress, and endothelial dysfunction are far bigger threats to testosterone production than modest LDL reduction.

Risk of Diabetes

The concern about statin-induced diabetes is grounded in real data—but context is everything.

Statins, especially at high doses, may cause a modest increase in blood glucose levels by reducing insulin sensitivity and possibly impairing pancreatic beta-cell function. The absolute risk? Roughly one additional case of type 2 diabetes per 255 patients treated annually, primarily among people with existing risk factors like metabolic syndrome, obesity, or prediabetes¹¹.

That said, these same individuals are also at the highest risk for cardiovascular events, and statins reduce that risk substantially. In fact, for every new case of diabetes caused by statins, five to six major cardiovascular events are prevented. It’s a clear net benefit—especially if paired with lifestyle interventions like resistance training, carbohydrate moderation, and walking after meals to mitigate blood sugar spikes.

If you're metabolically healthy and active, the diabetes risk is exceedingly small—but it’s worth monitoring fasting glucose and A1C yearly while on therapy.

Statins and Brain Health: Myth vs. Reality

One of the most persistent myths about statins is that they impair brain function—causing memory loss, brain fog, or even increasing the risk of dementia. This fear often stems from the fact that cholesterol is abundant in the brain, and it’s true: cholesterol plays a key role in myelin production, synapse formation, and overall neuronal function.

But here’s the key point—statins don’t significantly affect brain cholesterol levels. That’s because the brain makes its own cholesterol, independent of blood cholesterol. Most statins, especially hydrophilic ones like rosuvastatin and pravastatin, don’t readily cross the blood–brain barrier, and even the more lipophilic statins like simvastatin have shown no consistent link to cognitive decline in controlled studies¹⁵.

In fact, some research suggests statins may protect the brain, particularly by reducing the risk of stroke, microvascular disease, and Alzheimer’s pathology linked to vascular dysfunction. A 2021 meta-analysis found no association between statin use and cognitive decline, and some studies even show reduced dementia risk in statin users¹⁶. The FDA reviewed this concern and concluded that any cognitive side effects are rare, reversible, and not supported by robust evidence.

Performance and Libido

So what about the stuff you actually care about—like energy, drive, strength, and morning wood?

In well-designed studies, statins have not been shown to impair sexual function or strength gains in men without pre-existing conditions. One 2020 meta-analysis found no impact on erectile function, and some even showed improvements when statins were used to manage vascular risk in men with ED¹⁴.

What does affect performance? Poor sleep, low protein intake, insulin resistance, and overtraining. These are the real testosterone thieves. Statins, at moderate doses, are unlikely to interfere unless you're also under-eating, over-training, and neglecting recovery.

If you're still concerned, consider:

• Using lower or intermittent dosing of rosuvastatin or pitavastatin

• Supplementing with zinc, magnesium, vitamin D, and CoQ10

• Monitoring total and free T, LH, SHBG, and inflammation markers over tim

Why It Matters for Hunters and Anglers

You’re probably asking: “If I’m fit, active, and don’t smoke, do I really need to worry about this?”

Absolutely. Many of the hunters I work with are walking around with normal LDL-C but high ApoB or LDL-P—often due to genetics, diet, or visceral fat. Even ketogenic or carnivore diets can increase LDL-P in some individuals¹².

Being lean helps, but plaque builds silently. For many, the first symptom is sudden death.

Tactical Longevity: When to Consider a Statin

You might consider a statin if:

• Your ApoB > 90 mg/dL, especially with other risk factors

• Your LDL-P > 1,000 nmol/L

• You’ve had a CAC score > 0 or proven plaque on CT angiography

• You have family history or metabolic syndrome

Statins like rosuvastatin (5–10 mg) or pitavastatin (2 mg) a few times per week may offer strong protection with minimal side effects when monitored.

But What About Supplements?

Red yeast rice, bergamot, and berberine can lower LDL-C modestly, but they don’t lower ApoB or LDL-P to the same extent as statins, and quality control is often poor. They may be useful in borderline cases or statin-intolerant individuals—but they’re not enough alone in high-risk cases¹³.

The Aging Wild Bottom Line

If you want to hike into elk camp in your 70s and still get up at 4 a.m. to chase steelhead, you need to protect your arteries now.

• Don’t rely on basic cholesterol panels

• Measure ApoB and LDL particle count

• Don’t fear statins—use them like gear: smart, light, and intentional

• Supplement when appropriate—but don’t gamble with plaque

In our next post, we’ll cover coronary artery calcium scoring and CT coronary angiography—the imaging tools that show what’s really happening inside your arteries.

Because true longevity isn’t about looking good in your 40s.

It’s about still being able to get after it in your 70s.

References

1. Sniderman AD, et al. "Apolipoprotein B vs LDL cholesterol in cardiovascular risk assessment." JAMA Cardiol. 2019.

2. Ference BA, et al. "Low-density lipoproteins cause atherosclerotic cardiovascular disease." Eur Heart J. 2017;38(32):2459–2472.

3. Otvos JD, et al. "LDL particle concentration and risk for coronary events." Am J Cardiol. 2002;90(8):893–896.

4. Istvan ES, Deisenhofer J. "Structural mechanism for statin inhibition of HMG-CoA reductase." Science. 2001;292(5519):1160–1164.

5. Cholesterol Treatment Trialists’ Collaboration. "Efficacy and safety of statin therapy." Lancet. 2010;376(9753):1670–1681.

6. Collins R, et al. "Interpretation of the evidence for the efficacy and safety of statin therapy." Lancet. 2016;388(10059):2532–2561.

7. Banach M, et al. "Statin intolerance–an attempt at a unified definition." J Am Coll Cardiol. 2015;67(23):2690–2700.

8. Stroes ES, et al. "Statin-associated muscle symptoms: impact on statin therapy." Eur Heart J. 2015;36(17):1012–1022.

9. Marcoff L, Thompson PD. "The role of Coenzyme Q10 in statin-associated myopathy." J Am Coll Cardiol. 2007;49(23):2231–2237.

10. Bruckert E, et al. "Effects of lipid-lowering drugs on testosterone levels." Eur J Endocrinol. 2005;152(3):319–324.

11. Preiss D, et al. "Risk of incident diabetes with intensive-dose statin therapy." JAMA. 2011;305(24):2556–2564.

12. Dayspring TD. "Lipidology 101: Understanding advanced lipid testing." Lecture Series. Foundation for Health Improvement and Technology, 2020.

13. Cicero AFG, et al. "Nutraceuticals and cholesterol lowering: An evidence-based approach." Pharmacol Res. 2016;110:57–69.